Repetitive intrathecal injection of human NMO-IgG with complement exacerbates disease severity with NMO pathology in experimental allergic encephalomyelitis mice

• Published in: Multiple sclerosis and related disorders Vol. 30; pp. 225 - 230
• Main Authors: Lee, Chao-Lin, Wang, Kai-Chen, Chen, Shyi-Jou, Chen, Chieh-Min, Tsai, Ching-Piao, Chen, Shao-Yuan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2019
• Subjects: Complement; EAE; NMO-IgG; EAE; NMO-IgG; Complement
• ISSN: 2211-0348; 2211-0356; 2211-0356
• DOI: 10.1016/j.msard.2019.02.025

•We provide a novel animal model of NMO by intrathecal injection of NMO-IgG into EAE mice.•This animal model closely recapitulates human NMO pathology with relevant clinical severity.•The results imply that NMO-IgG is a key role of the immune response and clinical severity of NMO. Neuromyelitis optica (NMO) is recognized as a different CNS autoimmune disease from multiple sclerosis (MS). Whether NMO-IgG contributes directly to the pathogenesis of NMO or is just a serologic marker of autoimmune responses of the disease needs to be clarified. We created MOG-induced experimental autoimmune encephalomyelitis (EAE) mice by passively transferring NMO-IgG to model the pathogenic findings in NMO patients. The mice were divided into three groups and administered intrathecal PBS, human complement with IgG from normal subjects, or IgG from AQP4(+) patients on days 8 and 11 after immunization. The EAE scores of EAE mice with intrathecal NMO-IgG injection were significantly elevated 14 days post-immunization. All of the mice were sacrificed for brain and spinal cord pathology analysis on day 21 post-immunization. Compared to mice given normal human IgG, EAE mice injected with NMO-IgG had markedly decreased AQP4 and glial fibrillary acidic protein (GFAP) expression and fluorescent intensity in the brain and spinal cord but more scattered deposition of complement (C9neo). Thus, our studies not only support the pathogenic role of NMO-IgG with complement in NMO disease but also provide a platform for the development of future therapeutics.